Pharmaceutical Technology, Nov 1, 2009 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology, Nov 1, 2009
Articles
Technology Forecast for Injectables
By Michelle Hoffman
A Conversation with Greystone Associates' George Perros. This article contains bonus online-exclusive material.
Plastic Prefilled Syringes: A Better Fit for Autoinjector Systems
By Douglas Stout , Vinod Vilivalam
The authors describe the ways in which plastic prefilled syringes can be an alternative that provides consistent performance, protects drugs prone to degradation, and enhances patient safety.
Current Perspectives on Aseptic Formulations
By Dave Abram
The author details the factors in formulation design, requirements in facilites and equipment, and validation criteria for aseptic formualtions.
Risk Management for Aseptic Processing
By Ed White
The author discusses the risks involved with aseptic processing, methods and tools used to identify and control risk, and regulatory guidelines relevant to the risk-management process.
Challenges and Strategies for Implementing Automated Visual Inspection for Biopharmaceuticals
By Nitin Rathore , Cylia Chen , Oscar Gonzalez , Wenchang Ji
The authors used a light-transmission-based static division system to detect particles of foreign contaminants in prefilled vials.
Targeting Therapeutics for the Middle and Inner Ear
By Michelle Hoffman
A Conversation with Otonomy
From Needle to Pill: Reformulating Injectable Drugs for Oral Delivery
By Anna Nolan
The author describes how Merrion Pharmaceuticals reformulates parenteral drugs into tablets and capsules that are easier for patients to take and provide better bioavailability.
USP's Ferrules and Caps Labeling Changes Put on Hold
By Frederick J. Balboni, Jr.
This article provides an update to the author's Viewpoint column, "Changes to Vial Labels May Affect Patient Safety," which ran in Pharmaceutical Technology's March 2009 issue.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Click here